EC
NAMS icon

Eleva Capital’s NewAmsterdam Pharma NAMS Stock Holding History

Eleva Capital’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$823K Hold
25,721
– – 0.24% 14
2026
Q1 		$823K Buy
+25,721
New +$838K 0.24% 14

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Eleva Capital's NAMS Position: Q2 2026 in Review

Eleva Capital held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 25,721 shares worth $823K. The position accounts for 0.24% of the portfolio, ranked #14.

Eleva Capital first reported a position in NAMS in Q1 2026 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Eleva Capital held 25,721 shares of NewAmsterdam Pharma worth $823K as of Q2 2026.
  • Eleva Capital left its NewAmsterdam Pharma share count unchanged in Q2 2026.
  • NewAmsterdam Pharma made up 0.24% of Eleva Capital's portfolio in Q2 2026, its #14 holding.
  • Eleva Capital first reported a position in NewAmsterdam Pharma in Q1 2026 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Eleva Capital's 13F filing for Q2 2026, filed 2 Jul 2026.